Design, Synthesis and Pharmacological Evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a Novel Triple Angiokinase Inhibitor for Cancer Therapy

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2020 Sep 23

PMID 32963943

Citations 6

Authors

Yuqin Yao

Zhuowei Liu

Manyu Zhao

Zhengxia Chen

Peng Li

Yang Zhang

Yuxi Wang

Chengjian Zhao

Chaofeng Long

Xiaoxin Chen

Jinliang Yang

Affiliations

Soon will be listed here.

Abstract

Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we presented the design, synthesis, target identification, molecular mechanism, pharmacodynamics (PD) and pharmacokinetics (PK) research of a novel triple-angiokinase inhibitor WXFL-152. WXFL-152, identified from a series of 4-oxyquinoline derivatives based on a structure-activity relationship study, inhibited the proliferation of vascular endothelial cells (ECs) and pericytes by blocking the angiokinase signals VEGF/VEGFR2, FGF/FGFRs and PDGF/PDGFR simultaneously . Significant anticancer effects of WXFL-152 were confirmed in multiple preclinical tumor xenograft models, including a patient-derived tumor xenograft (PDX) model. Pharmacokinetic studies of WXFL-152 demonstrated high favourable bioavailability with single-dose and continuous multi-dose by oral administration in rats and beagles. In conclusion, WXFL-152, which is currently in phase Ib clinical trials, is a novel and effective triple-angiokinase inhibitor with clear PD and PK in tumor therapy.

Citing Articles

Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents.

Chaudhari P, Nemade A, Shirkhedkar A RSC Adv. 2024; 14(45):33384-33417.

PMID: 39439843 PMC: 11495155. DOI: 10.1039/d4ra05244g.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.

Fang F, Dai Y, Wang H, Ji Y, Liang X, Peng X Acta Pharm Sin B. 2023; 13(12):4918-4933.

PMID: 38045061 PMC: 10692477. DOI: 10.1016/j.apsb.2023.10.002.

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer.

Hou Z, Lin J, Ma Y, Fang H, Wu Y, Chen Z Front Pharmacol. 2023; 14:1193791.

PMID: 37324492 PMC: 10267405. DOI: 10.3389/fphar.2023.1193791.

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.

Liu Z, Chen H, Zheng L, Sun L, Shi L Signal Transduct Target Ther. 2023; 8(1):198.

PMID: 37169756 PMC: 10175505. DOI: 10.1038/s41392-023-01460-1.

Targeting fibrosis, mechanisms and cilinical trials.

Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H Signal Transduct Target Ther. 2022; 7(1):206.

PMID: 35773269 PMC: 9247101. DOI: 10.1038/s41392-022-01070-3.

References

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

Chen H, Cong Q, Du Z, Liao W, Zhang L, Yao Y . Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Lett. 2016; 382(1):44-52. DOI: 10.1016/j.canlet.2016.08.020. View

Cao Y, Cao R, Hedlund E . R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl). 2008; 86(7):785-9. DOI: 10.1007/s00109-008-0337-z. View

de Palma M, Biziato D, Petrova T . Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17(8):457-474. DOI: 10.1038/nrc.2017.51. View

Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H . Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2003; 18(2):338-40. DOI: 10.1096/fj.03-0271fje. View

Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R . Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003; 162(6):1913-26. PMC: 1868139. DOI: 10.1016/S0002-9440(10)64325-8. View

Nissen L, Cao R, Hedlund E, Wang Z, Zhao X, Wetterskog D . Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007; 117(10):2766-77. PMC: 1994630. DOI: 10.1172/JCI32479. View

Ma W, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C . A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2018; 42(2):184-189. PMC: 6345595. DOI: 10.1097/COC.0000000000000492. View

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

10.

Shibuya M . VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol. 2013; 5(10):a009092. PMC: 3783052. DOI: 10.1101/cshperspect.a009092. View

11.

Frentzas S, Simoneau E, Bridgeman V, Vermeulen P, Foo S, Kostaras E . Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016; 22(11):1294-1302. PMC: 5104270. DOI: 10.1038/nm.4197. View

12.

Jiang Z, Wang L, Liu X, Chen C, Wang B, Wang W . Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. Acta Pharm Sin B. 2020; 10(3):488-497. PMC: 7049616. DOI: 10.1016/j.apsb.2019.10.004. View

13.

Glen H, Mason S, Patel H, Macleod K, Brunton V . E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer. 2011; 11:309. PMC: 3154179. DOI: 10.1186/1471-2407-11-309. View

14.

Wei P, Liu B, Wang R, Gao Y, Li L, Ma Y . Discovery of a series of dimethoxybenzene FGFR inhibitors with 5pyrrolo[2,3-]pyrazine scaffold: structure-activity relationship, crystal structural characterization and study. Acta Pharm Sin B. 2019; 9(2):351-368. PMC: 6437634. DOI: 10.1016/j.apsb.2018.12.008. View

15.

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

16.

Duan J, Wang Z, Lin L, Li J, Wang Y, Bai H . Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. Invest New Drugs. 2019; 37(4):731-737. DOI: 10.1007/s10637-019-00735-1. View

17.

Lee H, Yun H, Kim S . Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372(19):1868. DOI: 10.1056/NEJMc1503150. View

18.

Fons P, Gueguen-Dorbes G, Herault J, Geronimi F, Tuyaret J, Frederique D . Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs. J Cell Physiol. 2014; 230(1):43-51. DOI: 10.1002/jcp.24656. View

19.

Ran C, Liu H, Hitoshi Y, Israel M . Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation. Cancer Res. 2013; 73(6):1831-43. DOI: 10.1158/0008-5472.CAN-12-2460. View

20.

Hu M, Zhou W, Wang Y, Yao D, Ye T, Yao Y . Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. Acta Pharm Sin B. 2020; 10(10):1943-1953. PMC: 7606109. DOI: 10.1016/j.apsb.2020.02.010. View